reports
- Jonathan Moreland
TTSH TILE SHOP HOLDINGS INC.
PLUG PLUG POWER INC.
MAIN MAIN STREET CAPITAL CORPORATION
PATK PATRICK INDUSTRIES INC.
ELY CALLAWAY GOLF COMPANY
UEIC UNIVERSAL ELECTRONICS INC.
UIHC UNITED INSURANCE HOLDINGS CORP.
FLWS 1-800-FLOWERS.COM CL A
SNDX SYNDAX PHARMACEUTICALS
NNBR NN
OCSL INC.
MPB OAKTREE SPECIALTY LENDING CORPORATION
ENR MID PENN BANCORP INC.
ZYME EDGEWELL PERSONAL CARE COMPANY
ARQT ZYMEWORKS INC.
HQL ARCUTIS BIOTHERAPEUTICS
ADV INC.
CVRX TEKLA LIFE SCIENCES INVESTORS
SRPT ADVANTAGE SOLUTIONS INC (A)
DMA CVRX
SUNS INC.
EVM SAREPTA THERAPEUTICS
TXO INC.
GF DESTRA MULTI ALTERNATIVE FUND
FG SUNRISE REALTY TRUST
IAE EATON VANCE INSD CALIF MUN BD FD
MORNINGSTAR PARTNERS
L.P.
THE NEW GERMANY FUND
INC.
F AND G ANNUITIES AND LIFE
INC.
ING ASIA PACIFIC HIGH DIVIDEND EQUITY INCOME FUND
Syndax Pharmaceuticals Inc: 4 directors
Four Directors at Syndax Pharmaceuticals Inc bought 29,765 shares at between 8.990USD and 9.112USD. The significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directo...
Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj® (...
Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) – Revumenib abstracts highlight compelling results in acute leukemia across the frontline and R/R setting and multiple genetic populations, including mNPM1, KMT2Ar, and NUP98r – – Axatilimab abstracts highlight the robust responses observed in different organs and subgroups of patients with chronic GVHD in the AGAVE-201 trial – NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovat...
Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Resear...
Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer - Dr. Nicholas Botwood comes to Syndax from BMS and brings 25 years of industry experience leading drug development, R&D strategy and global commercialization of novel oncology therapeutics - NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced the appointment of Dr. Nicholas Botwood BSc (Hons), MBBS, MFPM, FRCP, to the role of Head of Research a...
Syndax Announces Participation in May Investor Conferences
Syndax Announces Participation in May Investor Conferences NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in the following upcoming investor conferences: Bank of America Merrill Lynch Vegas Health Care Conference with a fireside chat on Thursday, May 15, 2025, at 9:20 a.m. PT/ 12:20 p.m. ET.TD Cowen 6th Annual Oncology Innovation ...
Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or ...
Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood – Primary endpoint met in R/R mNPM1 AML patients in pivotal Phase 2 portion of the AUGMENT-101 trial – – Robust remission rates in heavily pre-treated R/R mNPM1 AML population with nearly 50% overall response rate – – sNDA for revumenib in R/R mNPM1 AML submitted in April 2025 – NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced...
Syndax Reports First Quarter 2025 Financial Results and Provides Busin...
Syndax Reports First Quarter 2025 Financial Results and Provides Business Update – $20.0 million in Revuforj® (revumenib) net revenue in first full quarter of launch – – $13.6 million in Niktimvo™ (axatilimab-csfr) net revenue (reported by Incyte) in first partial quarter of launch – – Submitted sNDA for revumenib in R/R mNPM1 AML – – Initiated a pivotal frontline trial of revumenib plus ven/aza in mNPM1 and KMT2Ar AML – – $602.1 million in cash, cash equivalents and investments expected to fund the company to profitability – – Company to host a conference call today at 4:30 ...
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing ...
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) NEW YORK, May 02, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: ), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on May 1, 2025 the Company granted inducement awards to purchase up to 188,100 shares of common stock to seven new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th ...
Syndax to Announce First Quarter 2025 Financial Results and Host Confe...
Syndax to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 5, 2025 NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its first quarter 2025 financial results and provide a business update on Monday, May 5, 2025. In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Monday, May 5, 2025 to discuss the Compa...
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing ...
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) NEW YORK, April 04, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: ), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on April 1, 2025 the Company granted inducement awards to purchase up to 50,000 shares of common stock to four new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencemen...
Syndax Announces Participation at the Stifel 2025 Virtual Targeted Onc...
Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in a fireside chat at the Stifel 2025 Virtual Targeted Oncology Forum on Wednesday, April 9, 2025, at 10:30 a.m. ET. A live webcast of the fireside chat will be available in the Investo...
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing ...
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) NEW YORK, March 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: ), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on March 1, 2025 the Company granted inducement awards to purchase up to 282,000 shares of common stock to 12 new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement...
Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and...
Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update – $7.7 million in Revuforj® (revumenib) net product revenue in initial five weeks of launch – – Launched Niktimvo™ (axatilimab-csfr) in the U.S. in late January, in partnership with Incyte – – sNDA filing for revumenib in R/R mNPM1 AML expected in 2Q25 based on positive pivotal data from AUGMENT-101 trial – – $692.4 million in cash, cash equivalents and investments expected to fund the company to profitability – – Company to host a conference call today at 8:00 a.m. ET – NEW YORK, ...
Syndax Announces Participation in March Investor Conferences
Syndax Announces Participation in March Investor Conferences WALTHAM, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in the following upcoming investor conferences: TD Cowen 45th Annual Health Care Conference in Boston, MA, with a fireside chat on Tuesday, March 4, 2025, at 3:10 p.m. ETBarclays 27th Annual Global H...
Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results...
Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025 WALTHAM, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its fourth quarter and full year 2024 financial results and provide a business update on Monday, March 3, 2025. In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 8:00 a.m. ET on...
- Dave Nicoski
- Ross LaDuke
Vermilion Short Shots: Technically Vulnerable Stocks
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
DXCM DEXCOM INC.
PPG PPG INDUSTRIES INC.
CNHI CNH INDUSTRIAL NV
UCTT ULTRA CLEAN HOLDINGS INC.
QYM SOCIEDAD QUIMICA Y MINERA DE CHILE S.A. SERIES B ADS
SLAB SILICON LABORATORIES INC.
SEE SEALED AIR CORPORATION
SEDG SOLAREDGE TECHNOLOGIES INC.
SCL STEPAN COMPANY
RVNC REVANCE THERAPEUTICS INC.
PODD INSULET CORPORATION
MKSI MKS INSTRUMENTS INC.
MIDD MIDDLEBY CORPORATION
LGIH LGI HOMES INC.
HUN HUNTSMAN CORPORATION
HII HUNTINGTON INGALLS INDUSTRIES INC.
FELE FRANKLIN ELECTRIC CO. INC.
DIOD DIODES INCORPORATED
DGII DIGI INTERNATIONAL INC.
CSIQ CANADIAN SOLAR INC.
COO COOPER COMPANIES INC.
CMP COMPASS MINERALS INTERNATIONAL INC.
BMY BRISTOL-MYERS SQUIBB COMPANY
B BARNES GROUP INC.
AMBA AMBARELLA INC.
ALNY ALNYLAM PHARMACEUTICALS INC
ALB ALBEMARLE CORPORATION
MHK MOHAWK INDUSTRIES INC.
ERII ENERGY RECOVERY INC.
HPQ HP INC.
CG. CENTERRA GOLD INC.
FR. FIRST MAJESTIC SILVER CORP.
DOOR MASONITE INTERNATIONAL CORP.
LEG LEG IMMOBILIEN AG
ELY CALLAWAY GOLF COMPANY
FMC FMC CORPORATION
JKS JINKOSOLAR HOLDING CO. LTD. SPONSORED ADR
KMT KENNAMETAL INC.
TTC TORO COMPANY
XYL XYLEM INC.
AOS A. O. SMITH CORPORATION
ASIX ADVANSIX INC.
NOVT NOVANTA INC
SNDX SYNDAX PHARMACEUTICALS
IRTC IRHYTHM TECHNOLOGIES INC.
ASML ASML HOLDING N.V.
LTHM LIVENT
HROW HARROW HEALTH INC.
KROS KEROS THERAPEUTICS
MP MP MATERIALS CORP (A)
ALGM ALLEGRO MICROSYSTEMS
OI O-I GLASS INC
WOLF WOLFSPEED INC
TGI TGI INFRASTRUCTURES LTD
- Dave Nicoski
- Ross LaDuke
Vermilion Short Shots: Technically Vulnerable Stocks
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
SWK STANLEY BLACK & DECKER INC.
RGNX REGENXBIO INC.
RGP RESOURCES CONNECTION INC.
PLXS PLEXUS CORP.
PAYX PAYCHEX INC.
NVEE NV5 GLOBAL INC.
MMYT MAKEMYTRIP LTD.
MGRC MCGRATH RENTCORP
LNN LINDSAY CORPORATION
KRNT KORNIT DIGITAL LTD.
JRVR JAMES RIVER GROUP HOLDINGS LTD
HMN HORACE MANN EDUCATORS CORPORATION
BHLB BERKSHIRE HILLS BANCORP INC.
AOSL ALPHA & OMEGA SEMICONDUCTOR
ALB ALBEMARLE CORPORATION
BLUSD BELLUS HEALTH
EFR ENERGY FUELS
CLW CLEARWATER PAPER CORPORATION
SOM SOMNOMED
DLR DIGITAL REALTY TRUST INC.
LPLA LPL FINANCIAL HOLDINGS INC.
LPX LOUISIANA-PACIFIC CORPORATION
HRB H&R BLOCK INC.
WRB W. R. BERKLEY CORPORATION
BMTA BRITISH AMERICAN TOBACCO PLC ADS
SNDX SYNDAX PHARMACEUTICALS
RH RH
NTR NUTRIEN LTD.
ZS ZSCALER INC.
REPL REPLIMUNE GROUP
NTB BANK OF N.T. BUTTERFIELD & SON
DAVA ENDAVA PLC ADS
DDOG DATADOG INC CLASS A
DYN DYNE THERAPEUTICS
WSC WILLSCOT MOBILE MINI HOLDINGS CORP
CNXC CONCENTRIX
ZWS ZURN WATER SOLUTIONS CORP
J JACOBS SOLUTIONS INC.
WOLF META WOLF AG
MED IGEAMED SPA
ADP A DONG PAINT JSC
- Dave Nicoski
- Ross LaDuke
Vermilion Short Shots: Technically Vulnerable Stocks
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
AMN AMN HEALTHCARE SERVICES INC.
VET VERMILION ENERGY INC.
TTGT TECHTARGET INC.
TSN TYSON FOODS INC. CLASS A
RGNX REGENXBIO INC.
MDT MEDTRONIC PLC
LAZ LAZARD LTD CLASS A
KSS KOHL'S CORPORATION
JLL JONES LANG LASALLE INCORPORATED
ESS ESSEX PROPERTY TRUST INC.
DG DOLLAR GENERAL CORPORATION
CLFD CLEARFIELD INC.
BANF BANCFIRST
WFT. WEST FRASER TIMBER CO. LTD.
WD WALKER & DUNLOP INC.
CCRN CROSS COUNTRY HEALTHCARE INC.
MDRX ALLSCRIPTS HEALTHCARE SOLUTIONS INC.
BMTA BRITISH AMERICAN TOBACCO PLC ADS
SNDX SYNDAX PHARMACEUTICALS
MED MEDIFAST INC.
NTR NUTRIEN LTD.
HOG HARLEY-DAVIDSON INC.
CBR CABRAL GOLD INC
INVA INNOVIVA INC.
GH GUARDANT HEALTH
ALLO ALLOGENE THERAPEUTICS
CI CIGNA CORPORATION
SILK SILK ROAD MEDICAL
LHX L3HARRIS TECHNOLOGIES INC
BEAM BEAM THERAPEUTICS
LESL LESLIES
PRCT PROCEPT BIOROBOTICS CORP
VERV VERVE THERAPEUTICS INC
STER STERLING CHECK CORP
EVA ENVIVA PARTNERS LP
AMPS ALTUS POWER INC
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
Another Bear Market Rally Brewing? In last week's Compass (Sept. 27) we discussed our belief that the market indexes could see a bounce or pause in selling, citing numerous oversold indexes/Sectors that were testing critical supports, including 3636 on the S&P 500, $269 on the Nasdaq 100 (QQQ), and $162 on the Russell 2000 (IWM). Sector and index supports held, and early indications suggest a bear market rally is brewing, and potentially that the lows are in for this bear market, helped by shor...
EME EMCOR GROUP
XENE XENON PHARMACEUTICALS INC
SAGE SAGE THERAPEUTICS INC.
RVNC REVANCE THERAPEUTICS INC.
PTCT PTC THERAPEUTICS INC.
MCRB SERES THERAPEUTICS
GERN GERON CORP.
DY DYCOM INDUSTRIES INC.
AGIO AGIOS PHARMACEUTICALS INC.
ADMA ADMA BIOLOGICS INC
SNDX SYNDAX PHARMACEUTICALS
MYOV MYOVANT SCIENCE
KNSA KINIKSA PHARMACEUTICALS
AKRO AKERO THERAPEUTICS
PWR CAPTIVA VERDE WELLNESS CORP.
- Dave Nicoski
- Ross LaDuke
PAG PENSKE AUTOMOTIVE GROUP INC
MNRO MONRO INC
GPC GENUINE PARTS COMPANY
GERN GERON CORP.
CRMT AMERICA'S CAR-MART INC.
AZO AUTOZONE INC.
AN AUTONATION INC.
ADMA ADMA BIOLOGICS INC
BLUSD BELLUS HEALTH
SAH SONIC AUTOMOTIVE INC. CLASS A
LKO LAKES OIL N.L.
ORLY O'REILLY AUTOMOTIVE INC.
SNDX SYNDAX PHARMACEUTICALS
SIGA SIGA TECHNOLOGIES INC.
TCDA TRICIDA
MIRM MIRUM PHARMACEUTICALS
RAPT RAPT THERAPEUTICS
CLDX CELLDEX THERAPEUTICS INC.
KDNY CHINOOK THERAPEUTICS INC
PRTS CARPARTS.COM INC
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.